Docetaxel in breast cancer and a rationale for combination therapy

ONCOLOGY

Volumn 11, Issue 6 SUPPL., 1997, Pages 11-15

  Hortobágyi, Gabriel ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EDATREXATE; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; MELPHALAN; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; VINCRISTINE;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; DRUG RESEARCH; DRUG SCREENING; HUMAN; NONHUMAN; REVIEW;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; PACLITAXEL; TAXOIDS;

EID: 0030792548     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Data on file. Rhône-Poulenc Rorer Pharmaceuticals. Inc., Collegeville, PA.
2. Lavelle F, Brssery MC, Combeau C, et al. Preelinical evaluation of docetaxel (Taxotere). Semin Oncol 22(suppl 4):3-16, 1995.
3. Bissery MC, Nohynek G, Sanderink GJ. et al: Docetaxel (Taxotere): A review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 6:339-355, 1995.
4. Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13:2575-2581. 1995.
5. Vermorken JB, ten Bokkel Huinink WW, Mandjes IA, et al: High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: A European Cancer Center trial. Semin Oncol 22(4; suppl 8): 16-22. 1995.
6. Jones S, Winer E, Vogel C, et al: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer J Clin Oncol 13,2567-2574, 1995.
7. Bissery MC, Vrignaud P, Bayssas M, et al: Docetaxel (RP 56976, Taxotere) efficacy as a single agent or in combination against mammary tumors in mice (abstract 1946). Proc Am Assoc Cancer Res 35:327, 1994.
8. Antointe EC, Gozy M, Benhammouda A, et al: A phase II study of docetaxel and cislatin in anthracycline-pretreated metastatic breast cancer: Preliminary results Seventh International Congress on Anti-Cancer Treatment, Paris, France, Feb 3-6, 54: (abstract 2), 1997.
9. Diéras V, Gruia G, Pouillart P, et al- A phase I study of the combination of docetaxel and doxorubicin in 1st line CT treatment of metastatic breast cancer: Preliminary results (abstract 313). Breast Cancer Res Treat 37:91, 1996.
10. Fumoleau P, Delacroix V, Perrocheau G, et al: Docetaxel in combination with vinorelbinine as 1st line CT in patients with MBC: Preliminary results on 22 entered patients (abstract 314). Breast Cancer Res Treat 37:91, 1996.
11. Watanabe T, Adachi I, Sasaki Y, et al: A phase I/II study of docetaxel on combination with 5-fluorouracil for advanced or recurrent breast cancer (abstract 90P). Ann Oncol 7:21, 1996.
12. Ravdin PM: Taxoids: effective agents in anthracycline-resistant breast cancer. Semin Oncol 22(6, suppl 13):29-34, 1995
13. Bourgeois H, Gruia G, Dieras V, et al: Docetaxel (D) in combination with doxorubicin (Dx) as 1st line CT of metastatic breast cancer (MBC): A phase I dose finding study (abstract). Proc Anna Meet Am Soc Clin Oncol 15.A259, 1996.
14. Nabholtz J-M, Mackey JR, Smylie M, et al: Pilot study of Taxotere, doxorubicin, and cyclophosphamide (TAC) in metastatic breast cancer, in Taxotere (docetaxel), in Therapy of Breast Cancer and Other Solid Tumors. A Report from the Investigators' Meeting. Oncology 11(suppl 6)25-27, 1997.
15. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective amineoplastic agent in the management of patients with anthracycline-resistant metastattc breast cancer. J Clin Oncol 13:2886-2894, 1995.
16. Ravdin PM, Burris HA, Cook G, et at: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995.
17. Seidman AD, Norton L, Reichman BS, et al: Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colonystimulating factor in the treatment of breast cancer. Semin Oncol 20(4; suppl 3):40-45, 1993.
18. Gianni L, Munzone E, Capri G, et al: Pacli- taxel in metastatic breast cancer a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169-1175, 1995.
19. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion J Clin Oncol 12:1621-1629, 1994.
20. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867; 1994.
21. Degardin M, Bonneterre J, Hecquet B, et al: Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5:423-426: 1994.